p53 stability is regulated by HDM2, a RING domain protein that acts as an E3 ligase to ubiquitinate p53 and target its degradation. Phosphorylation of HDM2 on serine 166 by AKT has been shown to enhance HDM2 activity and promote the degradation of p53. Here, we show that MAPKAP kinase 2 (MK2) can phosphorylate HDM2 on serine 157 and 166 in vitro. Treatment of cells with anisomycin, which activates MK2, also results in phosphorylation of HDM2 on serine 157 and 166 in vivo. Mutation of the MK2 phosphorylation sites in HDM2 to aspartic acid renders HDM2 slightly more active in the degradation of p53, and mouse cells deficient for MK2 show reduced Mdm2 phosphorylation and elevated levels of p53 protein. Together, our results suggest that MK2 may act to dampen the extent and duration of the p53 response.
Introduction
The p53 protein plays an important role in suppressing tumor development by inhibiting the proliferation of stressed or damaged cells (Vousden, 2000) . In unstressed cells p53 function is inhibited -in part -through the interaction with HDM2, a protein that can regulate p53 function and stability (Kubbutat and Vousden, 1998; Michael and Oren, 2002) . HDM2 functions as a RING domain E3 ligase, capable of both mono-and polyubiquitination of p53 (Honda et al., 1997; Fang et al., 2000; Nakamura et al., 2000; Rodriguez et al., 2000; Lai et al., 2001; Li et al., 2003) . This activity of HDM2 contributes to both the degradation of p53 (Haupt et al., 1997; Kubbutat et al., 1997) and the nuclear export of the p53 protein (Boyd et al., 2000; Geyer et al., 2000; Gu et al., 2001; Lohrum et al., 2001) . Although p53 activity is regulated by several other mechanisms, including two further ubiquitin ligases Pirh2 and COP1 (Leng et al., 2003; Dornan et al., 2004) , in vivo studies have clearly illustrated the importance of HDM2 (Mdm2 in mice) in inhibiting p53 to allow normal growth and development (Jones et al., 1995; Montes de Oca Luna et al., 1995; Mendrysa et al., 2003) .
Activation of p53 in response to stress is accompanied by the stabilization of p53, which has been associated with the inhibition of HDM2's ability to target p53 for degradation. Several mechanisms to block HDM2 activity have been described, including the interaction of HDM2 with proteins such as ARF (Sherr, 1998) or L11 (Lohrum et al., 2003; Zhang et al., 2003) , or posttranslational modification of either p53 or HDM2 (Meek and Knippschild, 2003; Xu, 2003) . HDM2 is a highly phosphorylated protein, and several protein kinases have been identified that target HDM2 and regulate the activity of HDM2 towards p53. Many of these phosphorylation events on HDM2 have been shown to reduce the ability of HDM2 to target p53 for degradation, and so would be expected to contribute to the activation of the p53 response. For example, DNA damage activated kinases have been shown to contribute to the destabilization of HDM2 and subsequent activation of p53 (Stommel and Wahl, 2004) . However, hypophosphorylation in the central acidic domain of HDM2 following ionizing radiation has been associated with stabilization of p53, suggesting that phosphorylation may also play a role in activating HDM2 function (Blattner et al., 2002) . Indeed, phosphorylation of HDM2 by AKT has been associated with an enhanced ability of HDM2 to degrade p53 (Mayo and Donner, 2001; Zhou et al., 2001; Ashcroft et al., 2002) . This has been suggested to reflect a phosphorylation-induced translocation of HDM2 to the nucleus (Mayo and Donner, 2001 ) and an inhibition of HDM2 autoubiquitination and degradation (Feng et al., 2004) . This ability of AKT to activate HDM2 to degrade p53 is likely to contribute to the survival function of AKT (Lawlor and Alessi, 2001) .
Stress-induced activation of MAP kinase pathways has been shown to lead to phosphorylation of p53 and induction of a p53 response (Wu, 2004) . Both the p38 MAPK, and its downstream target MAPKAP kinase 2 (MK2), have been shown to phosphorylate p53 at sites that are associated with the stabilization and activation of p53 (Bulavin et al., 1999; She et al., 2000 She et al., , 2002 . We report here that MK2 can also phosphorylate HDM2 on serine 157 and 166. Phosphorylation of these sites appears to contribute to the activation of HDM2 and therefore a reduction in p53 stability, and may play a role in moderating the extent and duration of a stressinduced induction of the p53 response.
Results

MK2
phosphorylates HDM2 on serine 157 and S166 in vitro Activation of the stress-induced p38 pathway has been associated with the stabilization of p53, and so we set out to determine whether components of this kinase pathway could regulate HDM2 by direct phosphorylation. Initial experiments using bacterially expressed fragments of HDM2 and purified kinases showed that although p38 only weakly phosphorylated HDM2 (data not shown), MK2 (a downstream component of p38 signalling) was capable of phosphorylating full-length GST-tagged HDM2 in vitro (Figure 1a ). C-terminally truncated GST-tagged HDM2 proteins (1-127 and 1-162) showed that, while the HDM2 region 1-162 was also phosphorylated by MK2 (albeit slightly more weakly than the full-length protein), there was only very slight phosphorylation of HDM2 1-127. This suggested that there is at least one phosphorylation site between amino-acid positions 162 and the C-terminus of HDM2, and at least one further phosphorylation between amino acids 127 and 162. We were unable to identify a clear MK2 target sequence within HDM2 (hyd-x-R-x-x-S), although S157 is embedded in an amino-acid sequence (V-S-R-P-S) that somewhat resembles the MK2 consensus target sequence, although there is only one residue between the arginine and the target serine. We therefore tested the ability of MK2 to phosphorylate full-length HDM2 proteins harboring alanine mutations at either S157 (S157A) or the previously described AKT site within this region, S166 (S166A) (Figure 1b) . These experiments showed a clear reduction in the incorporation of radioactive phosphate by the S166A mutant, with a somewhat more modest reduction for the S157A mutant. In order to confirm the phosphorylation of these sites, we carried out HPLC analysis of tryptic digests generated after in vitro phosphorylation of the HDM2 proteins. Examination of the HDM2 protein subjected to p38 phosphorylation showed no clear peaks of activity, suggesting that the weak incorporation of radioactivity was nonspecific (data not shown). In contrast, MK2 phosphorylation of wild-type (wt) HDM2 revealed two clear peaks of activity (Figure 1c) . One of these peaks was lost when the S166A mutant was used as a substrate, while the second peak was lost following phosphorylation of the S157A. To verify S157 as a phosphorylation site, we performed a phosphoamino-acid analysis of the tryptic peptides from the elution fraction from peak 2 of both phosphorylated wild-type HDM2 and HDM2-S157T. This analysis showed that most 32 P counts were contained in a serine residue for the wild-type HDM2, and that this shifted to phosphorylation of threonine in HDM2-S157 T (Figure 1d ). GST-tagged wild-type HDM2 protein, HDM2-S166A and HDM2-S157A were phosphorylated with MK2 in vitro and separated on an 8% SDS-polyacrylamide gel (right panel). Equal expression of each protein was confirmed on a coomassie-stained gel (left panel). (c) HPLC analysis of tryptic peptides from 32 P-labelled HDM2 proteins. Two major peaks of activity are seen in the wild-type protein (labelled 1 and 2); peak 1 is lost in the S166A mutant and peak 2 is lost in the S157A mutant. (d) Phospho-amino acid analysis of wild-type HDM2 and HDM2-S157 T following phosphorylation with MK2 and AKT S157 and S166 are phosphorylated in vivo Having shown that MK2 can phosphorylate HDM2 on serines 157 and S166 in vitro, we sought to determine whether these sites can also be phosphorylated following activation of MK2 in cells. Endogenous HDM2 is usually expressed at low levels in most cells, so we established a series of U2OS cells that stably overexpressed HDM2 proteins, and further enhanced the levels of HDM2 protein by treating the cells with the proteasome inhibitor MG132, to stabilize HDM2. The cells were serum starved overnight and then stimulated with anisomycin, a drug that has been shown to activate a number of kinases including p38 and MK2 (Hazzalin et al., 1996 (Hazzalin et al., , 1998 (Figure 2a ). To assess phosphorylation on serine 166, we took advantage of a phosphospecific antibody to this residue, which clearly showed increased ability to recognize HDM2 after activation of MK2 ( Figure 2b) . A similar induction of serine 166 phosphorylation was also detected in response to UV treatment (see Figure 4a ), which also activates the p38 pathway (Tibbles and Woodgett, 1999) .
Since no equivalent antibody specific to HDM2 phosphorylated at serine 157 is available, we turned to orthophosphate labelling of cells expressing wild-type or the S157A mutant HDM2, immunoprecipitation of the HDM2 proteins and HPLC analysis, as described above. Under these conditions, three major peaks were observed for the wild-type protein (Figure 2c ). The second of these peaks was also seen following activation of AKT and has been shown in previous studies to correspond to phosphorylation of serine 166 (Ashcroft et al., 2002) . The third peak identified in the in vivo phosphorylation experiment was eliminated in the S157A HDM2 mutant (Figure 2c ), suggesting that this peak represents phosphorylation of HDM2 on serine 157, as seen in vitro. Taken together, these results indicate that HDM2 can be phosphorylated on both serine 157 and 166 in cells. Although these data are consistent with phosphorylation of these sites by MK2, we cannot rule out a contribution of other kinases that are also activated by anisomycin, such as ribosomal S6 kinase or JNK.
Modulation of HDM2 activity by modification of serine 157 and 166
Previous studies have indicated that serine 166 phosphorylation of HDM2 enhanced p53 degradation activity, and we considered the possibility that phosphorylation of HDM2 at serine 157 might also affect HDM2 function, or modulate the effect of serine 166 phosphorylation. Coexpression of p53 and HDM2 in U2OS cells resulted in the expected degradation of p53 (Figure 3a) . Mutation of either serine 157 or 166 in HDM2 to alanine, to prevent phosphorylation, resulted in a slightly reduced p53 degradation activity. In contrast, mutation of serine 157 and 166 to aspartic acid, to mimic phosphorylation (S157D or S166D), resulted in a slightly enhanced reduction in p53 protein levels (Figure 3a ). Although these effects were weak, they were reproducibly observed in numerous such experiments in different cell types. The double mutants (S157A/S166A and S157D/S166D) did not show further enhancement or impairment of HDM2 function (data not shown), suggesting that there is no additive effect of those phosphorylation events.
The cotransfection experiment suggested that phosphorylation on S157 and/or S166 might lead to a more active form of HDM2 with regard to its ability to degrade p53. However, an in vitro ubiquitination assay using in vitro translated p53 as a substrate and bacterially purified HDM2-S157A and S157D revealed no significant differences from wild-type HDM2 in the ability of these HDM2 mutants to ubiquitinate p53 (Figure 3b ). It therefore seems likely that the relatively subtle effect of the modification of serine 157 and 166 is only manifested in cells. Serine 166 phosphorylation has Figure 2 HDM2 is phosphorylated on S157 and S166 in vivo in response to anisomycin. (a) U2OS cells were serum starved overnight and treated with anisomycin or left untreated for 6 h. Western blots were performed using the indicated antibodies. (b) U2OS cells were serum starved overnight and treated with anisomycin for the indicated times. HDM2 was immunoprecipitated and immunoblotted using the indicated antibodies. (c) U2OS cells stably expressing wild-type HDM2 and HDM2-S157A were serum starved for 12 h. Following 32 P-orthophosphate labelling for 6 h, MG132 treatment for 4 h (to stabilize the endogenous HDM2) and anisomycin treatment for 30 min (to activate p38/MK2), HDM2 protein was immunoprecipitated and prepared for HPLC as above previously been shown to enhance the nuclear localization of HDM2 (Mayo and Donner, 2001 ), but we were unable to detect a clear difference in the subcellular localization of these HDM2 mutant proteins in these cell systems (data not shown).
Previous studies have shown that HDM2 serine 166 is phosphorylated by AKT, and this phosphorylation can be detected in cells that are maintained in serum (Feng et al., 2004) . However, the slightly enhanced activity of the S166D mutant in the degradation of p53 suggests that this AKT-mediated phosphorylation may not be complete; therefore, we tested the effect of treatment with anisomycin on serine 166 phosphorylation in the presence and absence of serum ( Figure 3c ). As expected, cells grown in serum showed higher basal levels of serine 166 phosphorylation than serum-starved cells. However, treatment with anisomycin showed some ability to enhance the level of serine 166 phosphorylation in both the presence and absence of serum, suggesting that activation of MK2 or other anisomycin-stimulated kinases can phosphorylate HDM2, even in the presence of growth factor signalling.
Activation of the p38 stress pathway does not necessarily result in stabilization of p53
The ability of MK2 to phosphorylate HDM2 at sites that activate HDM2 function appeared to be inconsistent with the general observation that stress signalling leads to the inhibition of HDM2 and so stabilization of p53. The p38 pathway is induced by a number of stress signals, including UV and anisomycin, and exposure of cells to both anisomycin and UV resulted in phosphorylation of HDM2 at serine 166 (Figure 4a ). However, despite the similarity in induction of HDM2 phosphorylation, these two treatments did not have the same effect on p53 stability ( Figure 4b ). As shown in many previous studies, UV treatment resulted in the stabilization of p53. However, treatment of cells with anisomycin ). Proteins were analysed by Western blot using the indicated antibodies Figure 3 Phosphomimetic HDM2 mutants are more active in the degradation of p53. (a) U2OS cells were transiently co-transfected with 100 ng Flag tagged p53, GFP and 0.2 or 0.8 mg of wild-type HDM2, HDM2-S157A, HDM2-S166A, HDM2-S157D, or HDM2-S166D. Western blot analysis was performed using the indicated antibodies. Quantification of the amount of p53 is shown, relative to p53 levels in the absence of co-transfected HDM2. (b) In vitro ubiquitination of p53 by wild-type HDM2, HDM2-S157A and HDM2-S157D. p53 was translated in vitro and used as a substrate for ubiquitination by wild-type HDM2, HDM2-S157A or HDM2-S157D in the presence or absence of E2, as indicated. (c) U2OS cells were serum starved or left in serum overnight. The next day, cells were treated with anisomycin and lysed in NP40 lysis buffer after the indicated time points. HDM2 was immunoprecipitated and Western blotted using the indicated antibodies did not lead to a similar increase in p53 protein levels. Indeed, p53 levels were found to decrease in response to anisomycin, although this may partially reflect a concomitant decrease in the overall levels of protein synthesis to about 50% of that seen in untreated cells.
Since the p38 pathway is induced by both UV and anisomycin, it seemed likely that additional signals induced by these two treatments were responsible for the differences in effects on p53 stability. This possibility is underlined by the observation that UV treatment clearly resulted in the activation of kinases that allowed the phosphorylation of p53 on serine 15, while this activity was absent from the cells treated with anisomycin (Figure 4b ). These results serve to emphasize that the effect of activation of one kinase on p53 stability is strongly influenced by the activity of other kinase pathways.
Loss of MK2 leads to the stabilization of p53
To determine the importance of MK2 in the phosphorylation of HDM2, we turned to embryonic fibroblasts derived from MK2-deficient mice (Kotlyarov et al., 1999) . Using immortalized fibroblasts from these mice, we were able to show that anisomycin-induced phosphorylation of the endogenous mouse Mdm2 at the equivalent site to serine 166 (serine 163 in mouse Mdm2) was reduced in the MK2 null cells, compared to wildtype cells (Figure 5a ). Since both MK2 and AKT can phosphorylate serine 166 of Mdm2, we examined the relative contributions of each of these kinases in Mdm2 phosphorylation in response to anisomycin (Figure 5b) . Inhibition of the AKT pathway using the PI3 kinase inhibitor LY294002 did not affect serine 166 phosphorylation in wild-type cells. However, in MK2 null cells, the lower levels of serine 166 phosphorylation were further reduced following treatment with LY294002, indicating that the residual phosphorylation seen in the absence of MK2 is carried out by AKT.
Our results suggest that activation of MK2, one of the components of the p38 stress response pathway, can contribute to the phosphorylation of HDM2 at sites that enhance the degradation of p53. This apparently paradoxical activity of MK2 may reflect a mechanism to dampen the p53 response in relatively unstressed cells, or allow the inhibition of p53 once a stress signal has been resolved. Since the immortalized mouse embryonic fibroblast cells are likely to have some perturbation in the p53 pathway to allow immortalization, we examined the levels of p53 in primary mouse embryonic fibroblasts from wild-type and MK2-deficient mice. MK2-deficient cells showed slightly higher endogenous p53 levels than their wild-type counterparts and an enhanced ability to stabilize p53 in response to the UV (Figure 5c ). This effect, while clearly reproducible, was generally found to be relatively subtle. The enhanced induction of p53 correlated with an increased sensitivity of serum-starved MK2-deficient MEFs to UV-induced apoptosis (Figure 5d ). In the presence of serum, this differential in apoptotic sensitivity was less evident (data not shown).
Discussion
We report here that MK2 can phosphorylate HDM2 on serine 157 and 166 in vitro, and that the same sites are phosphorylated in cells treated with anisomycin, an activator of the p38/MK2 pathway. The consequence of these modifications is to enhance the ability of HDM2 to degrade p53, and cells lacking MK2 show higher levels of p53 and a more pronounced stabilization of p53 and apoptosis in response to UV.
Previous studies have shown that HDM2 can be phosphorylated on serine 166 by AKT, resulting in an increase in HDM2 activity associated with an enhanced accumulation of nuclear HDM2. Recently, DAP kinase has also been shown to be capable of phosphorylating HDM2 on serine 166 (Burch et al., 2004) . Our identification of MK2 as a kinase that can target serine 166, and the identification of serine 157 as a target for phosphorylation within HDM2, suggests that this region of HDM2 plays a critical role in the regulation of HDM2 activity in response to numerous and disparate signals. The ability of HDM2 to target p53 for degradation depends on the p53-binding region in the N-terminus of HDM2 and the RING domain in the C-terminus of the protein, responsible for E3 ligase activity. Serine 157 and 166 fall outside both of these regions, and modification of these sites would not be expected to affect the HDM2/p53 interaction or the E3 ligase activity of the RING domain. This is supported by our demonstration that alanine or aspartic acid substitutions of serine 157 do not affect the ability of HDM2 to co-immunoprecipitate p53 or ubiquitinate p53 in an in vitro assay (Figure 3b ). It is possible that phosphorylation of these sites affects the subcellular localization of HDM2, although we were unable to detect any difference between the wild-type and mutant proteins after overexpression in cells. Alternatively, several studies have now shown that mutations in the central region of HDM2 can inhibit p53 degradation without affecting ubiquitination (Blattner et al., 2002) and that degradation of p53 by HDM2 can be regulated at a step subsequent to ubiquitination (Brignone et al., 2004; Glockzin et al., 2004) . It is therefore also possible that phosphorylation of HDM2 at serine 157 could affect these steps in p53 turnover.
AKT is a well-established survival factor and the ability of AKT to dampen p53 activity is consistent with its antiapoptotic activity. In contrast, the p38 pathway has been shown to contribute to cancer cell apoptosis (Olson and Hallahan, 2004) and the activation of p53 (Wu, 2004) . However, it is clear that the regulation of p53 levels is subtle and complex, and that various opposing effects allow a tight modulation of the level and extent of the response. Induction of p53 by genotoxic and other stress signals can be reversible (Linke et al., 1996; Bates et al., 1999) , and the reduction of p53 levels to allow cells to re-enter cell cycle if the damage is resolved appears to depend on HDM2 activity (Perry, 2004) . It is therefore possible that the induction of MK2 by UV may -to some extentcounteract the stabilization of p53 and contribute to a timely release from the p53 response. This suggestion is supported to some extent by the observation that cells lacking MK2 show elevated p53 levels, and an abnormally strong p53 response that was associated with enhanced sensitivity to UV-induced apoptosis.
However, p53 levels did fall even in the absence of MK2, indicating that there must be additional mechanisms to reduce p53 levels at the end of the stress response.
Finally, although our data are consistent with a role for MK2 in the phosphorylation and activation of HDM2, our experiments have suggested that other kinases activated by anisomycin may also share this activity. This is illustrated by the observation that in U2OS cells only a very slight reduction in serine 166 phosphorylation was seen after treatment with the p38 inhibitors SB202190 or SB203580 (data not shown). It seems possible that stress-induced activators of HDM2 will play as important and complex a role in the regulation of the p53 response as the more widely studied stress-induced inhibitors of HDM2. We have found that the effect of phosphorylation of HDM2 on the ability to degrade p53 can be quite subtle, and ultimately, the net response to different stimuli in terms of activation or inhibition of p53 is likely to depend on the combination of pathways that are activated. This can be seen by comparison of the response to anisomycin and UV treatment, both of which activate p38 and MK2 but lead to quite different effects on the stabilization of p53. Although activation of MK2 can result in phosphorylation of HDM2 and enhanced degradation of p53, the manifestation of this response will depend on which other signals are activated in coordination with MK2.
Materials and methods
Expression of GST-tagged proteins
Various C-terminally truncated GST-tagged HDM2 constructs were generated by polymerase chain reaction and cloning into the bacterial pGEX expression vector. Point mutations were introduced into GST-HDM2 at positions 157 and 166 using the Quickchange Site-directed Mutagenesis Kit (Stratagene), in accordance with the manufacturer's instructions. After transformation into BL21 Escherichia coli cells, the GST-HDM2 variants were induced and purified as described previously (Ashcroft et al., 2002) .
In vitro kinase assays and reverse-phase HPLC Purified HDM2 proteins were incubated with MK2 (Upstate) in kinase assay buffer (50 mM Tris, pH 7.4, 1 mM DTT, 1 mM EGTA, 100 mM NaCl) containing 10 mM (g-32 P)ATP. After the incubation at 301C for 30 min, the samples were resolved on an 8% SDS-polyacrylamide gel. Following exposure of the gel to X-ray film, the samples were cut out and isolated by reversephase HPLC on a C18 column as described previously (Ashcroft et al., 2002) .
Cell culture U2OS, MCF-7, primary and immortal mouse embryo fibroblasts were maintained in DMEM media containing 10% foetal calf serum. For transfections, cells were plated on 10 cm 2 dishes (0.8 Â 10 6 cells per plate) and transfected using calcium phosphate co-precipitation. For transient transfections, pEGFP-N1 (Clontech) was included to monitor transfection efficiency and protein loading. In order to obtain U2OS cells stably expressing various HDM2 variants, the U2OS cells were transfected as described above and subjected to antibiotic selection (G418) for 2 weeks. Resistant cells were pooled. Apoptosis was assessed by measuring the number of cells with sub-G1 DNA content by FACS, as described previously (Rowan et al., 1996) .
Protein analysis
Cells were lysed in 2xSDS lysis buffer and Western blot analysis performed using anti-HDM2 (AB1/AB2, Oncogene Science), anti-HDM2-P-ser166 (Cell Signaling Technology and Feng et al., 2004) , anti-flag (M5, Sigma) and anti-GFP (Clontech), where appropriate blots were probed using an anti-Cdk4 antibody (Santa Cruz) or an anti-actin antibody (Sigma) to monitor protein loading.
Anisomycin /UVC treatment and in vivo labelling U2OS cells expressing different HDM2 variants were plated on 10 cm 2 dishes (0.8 Â 10 6 cells per plate) and serum starved for 12 h. Cells were then treated with 1 mCi of [ 32 P]orthophosphate per ml of labelling medium for 6 h, 10 mM MG132 for 4 h to stabilize HDM2, and 25 ng/ml anisomycin for 30 min to active p38/MK2 kinase. Following immunoprecipitation of HDM2 using an anti-HDM2 antibodies (AB1/AB2, Oncogene), the HDM2 proteins were separated on a 8% SDS-polyacrylamide gel, cut out, digested with trypsin and separated into different elutions using HPLC as described above.
For UVC treatment, cells were serum starved or left in serum overnight. After aspiration of medium, cells were treated with UVC light.
In vitro ubiquitination assay
The in vitro ubiquitination assay was carried out as described previously (Fang et al., 2000) . Recombinant GST-HDM2 proteins were purified on glutathione-Sepharose, mixed with in vitro translated p53 and incubated at 41C for 1 h. After washing, beads were incubated with 200 ng UbcH5B, 50 ng rabbit E1 (Calbiochem), and 1 mg His-6-tagged ubiquitin (Calbiochem). After 1 h at 301C, the reaction was stopped by adding SDS-sample buffer and the resultant products resolved by SDS-PAGE.
Phospho-amino-acid analysis
Following in vitro phosphorylation by MK2 and AKT, HDM2 proteins were subject to tryptic digestion and HPLC analysis. Single fractions were lyophilized, and hydrolysed with 5.7 N HCL for 1 h at 1101C. The recovered phospho-amino acids were separated on a 2D-gel, as described elsewhere (Morrison et al., 1993) .
